AI Engines For more Details: Perplexity Kagi Labs You
Heart health: Safflower oil is rich in linoleic acid, an essential omega-6 fatty acid that has been linked to improved heart health. Linoleic acid helps reduce LDL (bad) cholesterol levels and may increase HDL (good) cholesterol levels, leading to a healthier lipid profile. By promoting better cholesterol balance, safflower oil consumption may lower the risk of cardiovascular diseases such as heart attacks and strokes.
Anti-inflammatory properties: The high concentration of linoleic acid in safflower oil contributes to its anti-inflammatory effects. Chronic inflammation is associated with various health conditions, including cardiovascular disease, arthritis, and certain cancers. Incorporating safflower oil into the diet may help reduce inflammation and alleviate symptoms associated with inflammatory conditions.
Weight management: Safflower oil is lower in saturated fats compared to some other cooking oils, making it a healthier option for individuals looking to manage their weight. Its high unsaturated fat content and low saturated fat content make it suitable for cooking methods that require high temperatures, such as frying and baking. Additionally, some studies suggest that safflower oil supplementation may aid in weight loss and abdominal fat reduction when combined with a calorie-controlled diet and regular exercise.
Blood sugar regulation: Safflower oil may have beneficial effects on blood sugar levels and insulin sensitivity, making it potentially useful for individuals with diabetes or those at risk of developing diabetes. Some research suggests that safflower oil supplementation may help improve glycemic control and reduce insulin resistance, although more studies are needed to confirm these effects fully.
Skin health: Safflower oil is commonly used in skincare products due to its moisturizing and nourishing properties. It is rich in linoleic acid, which helps maintain the integrity of the skin barrier and prevents moisture loss. Regular application of safflower oil topically or consumption as part of the diet may help improve skin hydration, elasticity, and overall appearance. It may also have anti-aging effects by reducing the appearance of wrinkles and fine lines.
Hair health: Safflower oil is beneficial for hair health due to its moisturizing and conditioning properties. It can help nourish the scalp, strengthen hair follicles, and prevent breakage and split ends. Massaging safflower oil into the scalp or using it as a hair mask may promote healthier, shinier hair and stimulate hair growth.
Liver health: Some animal studies suggest that safflower oil may have protective effects on liver health and reduce the risk of fatty liver disease. The anti-inflammatory and antioxidant properties of safflower oil may help prevent liver damage and improve liver function. However, more research is needed to determine its specific effects on human liver health.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | -0.2 | |
| Acne | 0.9 | 0.3 | 2 |
| ADHD | 1.9 | 1.5 | 0.27 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.4 | 0.5 |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.4 | 0.5 |
| Allergies | 1 | 1 | 0 |
| Allergy to milk products | 0.6 | 1 | -0.67 |
| Alopecia (Hair Loss) | 1.6 | -1.6 | |
| Alzheimer's disease | 5.2 | 3.4 | 0.53 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 3.6 | -2.6 |
| Ankylosing spondylitis | 1.8 | 2.8 | -0.56 |
| Anorexia Nervosa | 2.3 | 0.9 | 1.56 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 1 | 1.4 | -0.4 |
| Atherosclerosis | 0.8 | 0.2 | 3 |
| Atrial fibrillation | 1.2 | 2 | -0.67 |
| Autism | 4.6 | 4.4 | 0.05 |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Bipolar Disorder | 0.6 | 0.8 | -0.33 |
| Brain Trauma | 1 | 0.3 | 2.33 |
| Breast Cancer | 0.6 | 0.2 | 2 |
| Carcinoma | 1.2 | 1.6 | -0.33 |
| Celiac Disease | 2.8 | 0.8 | 2.5 |
| Cerebral Palsy | 1.2 | 0.8 | 0.5 |
| Chronic Fatigue Syndrome | 2.5 | 0.6 | 3.17 |
| Chronic Kidney Disease | 2 | 0.7 | 1.86 |
| Chronic Lyme | 0.2 | 0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 1.8 | -1.25 |
| Chronic Urticaria (Hives) | 0.6 | 0.6 | |
| Coagulation / Micro clot triggering bacteria | 1.8 | 0.2 | 8 |
| Colorectal Cancer | 0.2 | 1.4 | -6 |
| Constipation | 1.6 | 0.8 | 1 |
| Coronary artery disease | 2 | 1.4 | 0.43 |
| COVID-19 | 5.6 | 3 | 0.87 |
| Crohn's Disease | 5.1 | 3.8 | 0.34 |
| cystic fibrosis | 0.2 | 0.2 | |
| deep vein thrombosis | 1 | 1 | |
| Depression | 4.1 | 5.1 | -0.24 |
| Dermatomyositis | 0.4 | -0.4 | |
| Eczema | 0.8 | -0.8 | |
| Endometriosis | 0.7 | 1.4 | -1 |
| Eosinophilic Esophagitis | 0.7 | 0.7 | |
| Epilepsy | 2.8 | 3.1 | -0.11 |
| erectile dysfunction | 0.8 | -0.8 | |
| Fibromyalgia | 0.8 | 1.9 | -1.37 |
| Functional constipation / chronic idiopathic constipation | 2.2 | 2 | 0.1 |
| gallstone disease (gsd) | 0.2 | 1.2 | -5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.2 | 2 |
| Generalized anxiety disorder | 0.2 | 1 | -4 |
| Glioblastoma | 1 | 0.6 | 0.67 |
| Gout | 0.8 | 0.6 | 0.33 |
| Graves' disease | 2.7 | 1 | 1.7 |
| Halitosis | 0.4 | 0.9 | -1.25 |
| Hashimoto's thyroiditis | 0.4 | 3.4 | -7.5 |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.6 | -0.6 | |
| Hidradenitis Suppurativa | 0.2 | 0.4 | -1 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.8 | 0.6 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.5 | -1.5 |
| hyperglycemia | 2 | 0.6 | 2.33 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 1.2 | -1 |
| hypersomnia | 0.6 | 0.6 | |
| hypertension (High Blood Pressure | 4.2 | 1 | 3.2 |
| Hypothyroidism | 2 | 2 | |
| Hypoxia | 0.2 | 1.2 | -5 |
| IgA nephropathy (IgAN) | 0.6 | 0.6 | 0 |
| Inflammatory Bowel Disease | 2.9 | 0.8 | 2.62 |
| Insomnia | 0.6 | 1.4 | -1.33 |
| Intelligence | 1.4 | 1 | 0.4 |
| Intracranial aneurysms | 0.9 | -0.9 | |
| Irritable Bowel Syndrome | 2 | 1.7 | 0.18 |
| Liver Cirrhosis | 2 | 3.2 | -0.6 |
| Long COVID | 6.7 | 6.7 | 0 |
| Low bone mineral density | 1.2 | 0.4 | 2 |
| Lung Cancer | 1.9 | 1.9 | |
| ME/CFS with IBS | 0.2 | 0.2 | |
| ME/CFS without IBS | 0.2 | 0.2 | 0 |
| Metabolic Syndrome | 6.2 | 5.1 | 0.22 |
| Mood Disorders | 4.9 | 7.7 | -0.57 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | 0 |
| Multiple Sclerosis | 2.2 | 3 | -0.36 |
| Multiple system atrophy (MSA) | 0.6 | 0.8 | -0.33 |
| myasthenia gravis | 0.2 | -0.2 | |
| Neuropathy (all types) | 0.6 | 2.1 | -2.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.4 | 1.8 | 1.44 |
| Obesity | 4.3 | 3.5 | 0.23 |
| obsessive-compulsive disorder | 3.7 | 0.6 | 5.17 |
| Osteoarthritis | 0.8 | -0.8 | |
| Osteoporosis | 1.6 | 0.6 | 1.67 |
| Parkinson's Disease | 4.5 | 3.5 | 0.29 |
| Polycystic ovary syndrome | 0.8 | 3 | -2.75 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | 0 |
| Premenstrual dysphoric disorder | 0.2 | 0.8 | -3 |
| primary biliary cholangitis | 0.8 | -0.8 | |
| Psoriasis | 1.8 | 1.6 | 0.13 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4 | 5.3 | -0.32 |
| Rosacea | 0.2 | 0.2 | 0 |
| Schizophrenia | 2 | 4.1 | -1.05 |
| scoliosis | 0.2 | 0.8 | -3 |
| sensorineural hearing loss | 0.6 | 0.6 | |
| Sjögren syndrome | 1.8 | 1 | 0.8 |
| Sleep Apnea | 1.2 | 1.4 | -0.17 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | -0.2 | |
| Stress / posttraumatic stress disorder | 1.2 | 1.6 | -0.33 |
| Systemic Lupus Erythematosus | 3.1 | 2.6 | 0.19 |
| Tic Disorder | 1 | 0.2 | 4 |
| Tourette syndrome | 1.2 | -1.2 | |
| Type 1 Diabetes | 1.2 | 2.4 | -1 |
| Type 2 Diabetes | 3.4 | 4.9 | -0.44 |
| Ulcerative colitis | 4.5 | 1.8 | 1.5 |
| Unhealthy Ageing | 2 | 0.7 | 1.86 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.